
About Shennon Biotechnologies
Shennon Biotechnologies is a Healthcare company based in San Francisco (United States) founded in 2021. Developer of immune cell therapies against solid tumors and autoimmune disease. Shennon Biotechnologies has raised $25 million across 2 funding rounds from investors including Foundation Capital, AV8 Ventures and DCVC. Shennon Biotechnologies offers products and services including Single Cell Platform. Its focus areas include Life Sciences, Immunotherapy, Diversified and Oncology. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Shennon Biotechnologies was established in 2021 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where immune cell therapies are developed to address solid tumors and autoimmune diseases. Operations involve research and development of these therapies, with activities conducted primarily in the United States. The companys domain, shennonbio.com, supports its online presence in the field.
- Headquarters San Francisco, United States
- SectorsHealthcare
- Website shennonbio.com
- Social LinkedIn
- Total Equity Funding$25M (USD)
in 2 rounds
- Latest Funding Round$12M (USD), Seed
Sep 2026
- InvestorsFoundation Capital
& 7 more
Products & Services of Shennon Biotechnologies
Shennon Biotechnologies offers a comprehensive portfolio of products and services, including Single Cell Platform.
Profiles millions of immune cells to identify targets for therapies.
Funding Insights of Shennon Biotechnologies
Shennon Biotechnologies has successfully raised a total of $25M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $12 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25M
- Total Rounds 2
- Last Round Seed β $12M
- First Round $13M
(Mar 2023)
- Investors Count 8
All 2 funding rounds of Shennon Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | $12M | Seed | β | β | |
| Mar 2023 | $13M | Seed | β | DCVC |
8 investors in total: 8 institutional.
Investors in Shennon Biotechnologies
Shennon Biotechnologies has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Foundation Capital, AV8 Ventures and DCVC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on early-stage fintech, enterprise, web 3, consumer, and multiple sectors | 1995 | foundationcapital.com | Palo Alto, United States | |
Early-stage startups are supported by AV8 Ventures through investments. | 2021 | av8.vc | Palo Alto, United States | |
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
| future.ventures | ||||
| nextgenvp.com | ||||
| samos.vc | ||||
| atypical.com | ||||
| sarascapital.com |
Investor details for Shennon Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Shennon Biotechnologies
3 dated milestones of Shennon Biotechnologies across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Shennon Biotechnologies is founded.
- Funding First funding round of $13.0M.
- Funding Latest funding round, Seed, of $12.0M.
Competitors of Shennon Biotechnologies
Shennon Biotechnologies has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Shennon Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Shennon Biotechnologies
Websites that share an audience with Shennon Biotechnologies (shennonbio.com).
Websites whose visitors overlap most with Shennon Biotechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| r2mpharma.com | 100% | 2.9K | #4,331,217 | View details | |
| aligos.com | 100% | 3.4K | #3,982,602 | View details | |
| quantatx.com | 100% | 3.1K | #5,909,422 | View details | |
| excision.bio | 99% | 2.4K | #7,581,873 | View details | |
| astellasgenetherapies.com | 98% | 1K | View details | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 27 similar websites and full traffic analytics for Shennon Biotechnologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 27 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Shennon Biotechnologies (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Shennon Biotechnologies
Complete news archive for Shennon Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shennon Biotechnologies
Shennon Biotechnologies was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Shennon Biotechnologies is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Shennon Biotechnologies is a funded company, having raised a total of $25M across 2 funding rounds to date. The company's 1st funding round was a Seed of $13M, raised on Mar 2023.
Shennon Biotechnologies was established in 2021 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where immune cell therapies are developed to address solid tumors and autoimmune diseases. Operations involve research and development of these therapies, with activities conducted primarily in the United States. The companys domain, shennonbio.com, supports its online presence in the field.
Shennon Biotechnologies offers Single Cell Platform.
Shennon Biotechnologies has 8 investors. Key investors include Foundation Capital, AV8 Ventures, DCVC, Future Ventures, and NextGen Venture Partners.
